^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AlloStim (bioengineered allogeneic immune cells)

i
Associations
Company:
Immunovative
Drug class:
Immunostimulant
Related drugs:
Associations
Phase 2
Immunovative Therapies, Ltd.
Recruiting
Last update posted :
03/06/2024
Initiation :
07/12/2021
Primary completion :
11/01/2024
Completion :
04/01/2025
KRAS
|
KRAS wild-type • RAS wild-type
|
AlloStim (bioengineered allogeneic immune cells)
Phase 2a
Immunovative Therapies, Ltd.
Completed
Last update posted :
01/22/2020
Initiation :
09/01/2016
Primary completion :
03/01/2018
Completion :
09/01/2018
KRAS • BRAF
|
KRAS wild-type • RAS wild-type
|
AlloStim (bioengineered allogeneic immune cells)
Phase 2/3
Immunovative Therapies, Ltd.
Withdrawn
Last update posted :
01/22/2020
Initiation :
12/01/2017
Primary completion :
12/01/2019
Completion :
10/01/2020
KRAS • BRAF
|
KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type
|
Erbitux (cetuximab) • AlloStim (bioengineered allogeneic immune cells)
Phase 1/2
Immunovative Therapies, Ltd.
Withdrawn
Last update posted :
01/22/2020
Initiation :
03/01/2014
Primary completion :
03/01/2014
Completion :
03/01/2014
HER-2
|
capecitabine • AlloStim (bioengineered allogeneic immune cells)